Floatz logo

Dextromethorphan

Stroke Disorder

University of FloridaSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

128 Active assets in the Stroke Disorder cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Nerinetide
NoNO Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

Dextromethorphan is also rated in:

traumatic brain injuryDormant
BB
Indicative · Phase 4
69 / 100
View asset →
major depressive disorderActive
BB
Indicative · Phase 4
68 / 100
View asset →
treatment-refractory schizophreniaActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →